Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Recruiting
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
02/19/2025
Locations: John Hunter Children's Hospital, Newcastle, New South Wales +10 locations
Conditions: Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: a Prospective Registry with Central Echocardiography Analysis.
Recruiting
The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile de... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/19/2025
Locations: IUCPQ, Quebec, Not set
Conditions: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement
Stereotactic Radiotherapy (SBRT) of Lung Metastasis
Recruiting
The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up. SBRT has been in clinical use for over a decade in some institutions and the available data suggest that it can be used safely and with good results. This study will see how effective Stereotactic Body Radiation Therapy is for treating tumours in the lung and how often people have side effec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Princess Margaret Hospital, University Health Network, Toronto, Ontario
Conditions: Non-small Cell Lung Cancer, Metastasis From Other Cancers
Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients with Resistant Hypertension
Recruiting
Investigators hypothesize that CPAP treatment for suppressing OSAS in combination with a physical activity program will optimize 24-hour blood pressure control in patients with OSA-related resistant hypertension.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/18/2025
Locations: Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Not set +4 locations
Conditions: Hypertension, Resistant to Conventional Therapy, Sleep Apnea
A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases
Recruiting
This study will be a non-randomized phase II trial for patients with one to six brain metastases, at least one of which is appropriate for surgical resection. Upon registration, patients will be assigned to receive neo-adjuvant stereotactic radiosurgery (NASRS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University Health Network, Toronto, Ontario +1 locations
Conditions: Brain Metastases
Patient Specific Biomechanical Modeling of Abdominal Aortic Aneurysm to Improve Aortic Endovascular Repair
Recruiting
This project is aiming at the integration of a biomechanical computer program with a guidance code to simulate the endovascular repair (EVAR) procedure of abdominal aortic aneurysm (AAA). The computational time associated with finite element simulation generally renders its usage impractical for real-time application. Based on data collected during clinical interventions and a priori knowledge of AAA and endovascular device mechanical modeling, the investigators are proposing a deformable regist... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/18/2025
Locations: Centre Hospitalier de l'université de Montréal, Montréal, Quebec
Conditions: Aortic Aneurysm
Talazoparib and Thoracic RT for ES-SCLC
Recruiting
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy. Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Princess Margaret Cancer Center, University Health Network, Toronto, Ontario
Conditions: Lung Cancer, Small-Cell Lung Cancer
Priming CBT with RTMS for OCD
Recruiting
Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard first-line treatment for obsessive-compulsive disorder (OCD). Because CBT is a psychological treatment that aims to change patterns of thinking and behaving, it may be that improvement in cognitive functioning before treatment starts could lead CBT to be even more effective. One area of research that has shown potential benefit for OCD sufferers is rTMS. rT... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/18/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Obsessive Compulsive Disorder (OCD)
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Recruiting
The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Site 05, Vancouver, British Columbia +5 locations
Conditions: Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Non-Invasive Bladder Urothelial Carcinoma
68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy
Recruiting
Upper gastrointestinal (GI) cancers are a major health problem in Canada. At the metastatic stage, options are limited (usually chemotherapy, immunotherapy, personalized therapies under research protocols). These options are not applicable to all patients and may have significant toxicities. Endoradiotherapy (ERT) using a radioisotope coupled with a localization vector specifically targeting tumor cells to deliver a localized dose of radiation therapy is a promising avenue as it can treat dissem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: CIUSSS de l'Estrie- CHUS Hospital, Sherbrooke, Quebec
Conditions: Upper Digestive Tract Cancer
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
ALL
Ages:
Between 1 day and 30 days
Trial Updated:
02/18/2025
Locations: University of Alabama, Birmingham, Alabama +23 locations
Conditions: Congenital Heart Disease in Children
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
Recruiting
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec
Conditions: Metastatic Colorectal Cancer